GPN Vaccines’ technology is a proprietary engineered strain of S. pneumoniae that lacks capsular polysaccharide, is avirulent and is safe to handle; and when cultured and inactivated with high-energy photons (gamma-rays), a whole cell gamma-irradiated pneumococcal vaccine is produced which we call Gamma-PNTM. This whole cell vaccine is capable of inducing broad-spectrum T- and B-cell immunity to cross-reactive protein antigens of the pneumococcus that, when tested in experimental animals, is sufficient to provide protection against different pathogenic pneumococcal strains irrespective of strain serotype. The gamma-irradiation process used to inactivate (and kill) the vaccine strain provides an advantage over other inactivated S. pneumoniae vaccines because the structures of conserved surface protein antigens are maintained during vaccine production leading to effective induction of protective immunity.
David et al. 2019 Enhanced safety and immunogenicity of a psaA mutant whole-cell inactivated pneumococcal vaccine.
Immunol. Cell Biol. 97: 726-739
David et al. 2017 The effect of gamma-irradiation conditions on the immunogenicity of whole inactivated influenza A virus.
Vaccine 35: 1071-1079.
Babb et al. 2016 Enhanced protective responses to a serotype-independent pneumococcal vaccine when combined with an inactivated influenza vaccine.
Clinical Science 131: 169-180.
Babb et al. 2016. Intranasal vaccination with γ–irradiated Streptococcus pneumoniae whole-cell vaccine provides serotype-independent protection mediated by B-cells and innate IL-17 responses.
Clinical Science 130: 697-710.